You are here

Home » Resources

National TB Guidelines, Policies and Plans

Guideline for the Prevention of Mother to Child Transmission of Communicable Infections

Nov 2019
Guideline for the Prevention of Mother to Child Transmission of Communicable Infections

The challenge that PMTCT is currently facing is an increasing number of babies who acquire HIV infection during the postnatal period. To address this challenge, the guidelines provide guidance on the following:

  • Strengthening antenatal and postnatal care for both HIV negative and positive mothers.
  • The introduction of a dolutegravir-based ART regimen which is more efficacious in reducing the risks of transmission of HIV.
  • Promoting integrated management of the mother-baby pair by aligning PMTCT interventions with BANC visits during antenatal period and EPI visits during postnatal period.

These guidelines provide a framework for a service benefits package steering us towards the implementation of NHI. Therefore, we urge all clinicians, working in both public and private health facilities, to use these guidelines to offer quality, comprehensive services to the public.

Management of Rifampicin resistant Tuberculosis: A Clinical Reference Guide

Nov 2019
Management of Rifampicin resistant Tuberculosis: A Clinical Reference Guide

The past five years have seen revolutionary changes in the diagnosis and management of RR-TB, including the use of new and repurposed drugs and novel therapeutic approaches. South Africa has been a global leader in introducing innovation to the field of RR-TB and the work done in the country has had a significant impact on global policy. In 2018, for the first time ever, the World Health Organization (WHO) recommended the use of all-oral regimens for the treatment of RR-TB and issued guidance supporting the use of short-course, all-oral regimens under closely monitored conditions.

South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017

Oct 2019
South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017

The 2017 HIV and Health Study is the fifth wave of a series of cross-sectional surveys undertaken by a research consortium led by the Human Sciences Research Council (HSRC) every few years.

Multi-Drug Resistant TB: A Policy Framework on Decentralised and Deinstitutionalised Management for South Africa

May 2019
Multi-Drug Resistant TB: A Policy Framework on Decentralised and Deinstitutionalised Management for South Africa

This Policy Framework provides guidance to treat MDR-TB patients closer to their homes. It describes the need for and benefits for decentralisation and deinstitutionalisation of multidrug-resistant tuberculosis (MDR-TB) care and treatment. It also describes the necessary organisational structures and human resources requirements and expected functions of each level of operations. The monitoring and evaluation focus on the level and content of recording, reporting and monitoring indicators.

South African National LGBTI HIV Plan: 2017-2022

Oct 2018

The South African National LGBTI HIV Plan, 2017-2022 (LGBTI HIV Plan) is a milestone in the country’s response to HIV, AIDS, STIs, and TB. A national, multi-sectoral effort to address the linked HIV, TB and STI epidemics among Lesbian, Gay, Bisexual, Trans* and Intersex (LGBTI) people is urgent and somewhat overdue. Due to HIV vulnerabilities that are unique to each sub-group, there is a need for a strategic document that focuses on the LGBTI groups to support the National Strategic Plan on HIV, STIs and TB 2017-2022.

Interim Clinical Guidance for the Implementation of Injectable-Free Regimens for Rifampicin-Resistant Tuberculosis in Adults, Adolescents and Children

Oct 2018

This document provides interim clinical guidance on implementation of the modified short and long treatment regimens for people with Rifampicin Resistant Tuberculosis (RR-TB) in South Africa. National guidelines will be revised in 2019 following publication of the updated WHO policy guidelines on MDR-TB treatment (expected later in 2018).

NDOH Annual Performance Plan 2018/2019-2020/2021

Dec 2017

FOREWORD BY THE MINISTER OF HEALTH

If nobility is defined as having qualities or showing acts such as social justice, social solidarity, caring, honesty, generosity and courage to strive for what is good, then National Health Insurance (NHI) is not only a noble concept but a wise public investment for public good.

Summary Report on Decentralised and Deinstitutionalised Management of Multi-Drug Resistant Tuberculosis Services in South Africa

Oct 2017

Drug resistance is a major challenge in the control of Tuberculosis (TB), which itself remains a global public health concern. The incidence of Multi-drug Resistant (MDR) and Extensively Drug-resistant (XDR) TB is increasing, with an incidence rate of 70 per 100,000 people amidst a TB-HIV co-infection proportion estimated to be 60 to 80% in South Africa. In 2016 the World Health Organization (WHO) reported that South Africa has the 6th highest incidence of TB cases and the 5th highest number of Drug-Resistant TB cases in the world.

South Africa's National Strategic Plan on HIV, TB and STI's 2017-2022

Mar 2017
South Africa's National Strategic Plan on HIV, TB and STI's 2017-2022

The South African National Strategic Plan on HIV, TB and STIs 2017 - 2022 (NSP) serves as a roadmap for the next stage of our journey towards a future where these three diseases are no longer public health problems. This plan sets out the destinations – or goals – of our shared journey and establishes landmarks in the form of specific measurable objectives.

The purpose of the NSP is to enable the many thousands of organisations and individuals who drive the response to HIV, TB and STIs to act as a concerted force, moving in the same direction.

National Infection Prevention Control Guideline for TB, MDR-TB and XDR-TB

Dec 2015

Most people with undiagnosed, untreated and potentially contagious TB are frequently seen in health care facilities but are missed. In an area with high HIV prevalence, this poses a risk for HIV positive patients who are particularly vulnerable to TB with a 10% annual risk of developing TB compared to a 10% lifetime risk in those with normal immunity.

Pages